BA6b9 

BA6b9 is an allosteric inhibitor of SK4 channels that targets the CaM–PIP2-binding domain with a IC₅₀ value of 8.6 µM (WT SK4). BA6b9 inhibits SK4 channels by interacting with two specific residues, Arg191 and His192 in the S4–S5 linker. BA6b9 significantly prolongs atrial and atrioventricular effective refractory period (ERP) and reduces atrial fibrillation (AF) induction in rat isolated hearts, which has the potential to be used for the research of arrhythmia ^[1].

IC₅₀: 8.6 μM (WT SK4 Channel)^[1]

BA6b9 (10 μM) strongly inhibits calcium-activated SK4 channels by raising the EC₅₀ for Ca²⁺ activation from 65 nM to 435 nM ^[1].
BA6b9 (10 μM) exhibits a reduced heart rate, an increased PR interval, prolongation of atrial and atrioventricular effective refractory period (ERP) , and inhibits carbachol-induced atrial fibrillation (AF) in the Langendorff isolated heart model from adult male Sprague-Dawley rats (200-250 g) ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

233.31

C₁₄H₁₉NO₂

609335-29-7

O=C1OC2=C(N1CCCCCCC)C=CC=C2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Shira Burg, et al. Allosteric inhibitors targeting the calmodulin-PIP2 interface of SK4 K+ channels for atrial fibrillation treatment. Proc Natl Acad Sci U S A. 2022 Aug 23;119(34):e2202926119.